GLP-1 drugs, BMJ, Channel 4 Dispatches

[LittleGreyCat]

Grrr....something ate my first attempt!
Note - saved a draft, and I wasn't left with a save like a word processor where you save at regular intervals and keep editing. The whole thing disappeared.
I went to look for it.
Eventually found it in User Control Panel.
Option "view/edit" doesn't - just loads it. :evil:
Option "Load" allows you to edit. :crazy:

Anyway, moving on!

http://www.bmj.com/press-releases/2...s-about-safety-new-diabetes-drugs-and-speaks-

My partner saw this last night (late) and asked me about it.
I knew nothing.

The above link is a 'puff piece' for the program which has since aired.

New forms of diabetes drugs, known as GLP-1 based drugs, and promoted as “the new darlings of diabetes treatment” - make the pharmaceutical industry billions. But are they associated with an increased risk of cancer and do we know everything we should about these new treatments?

The BMJ and Channel 4 Dispatches investigated and found that evidence suggesting potential harm from the drugs in industry studies has not been published.

Some independent studies challenge the conclusions of the drugs manufacturers' own research. Now some medical experts and patient groups are calling on the pharmaceutical companies to be more transparent in reporting of study data and to enter into dialogue about safety concerns.

As a result, millions of patients around the world have not been fully informed about some of the possible risks.

http://en.wikipedia.org/wiki/Glucagon-like_peptide-1 talks about GLP-1 drugs.

http://www.fiercepharma.com/story/s...p-1-drugs-pancreatitis-reports-fda/2013-04-18 talks about safety concerns

Two months ago, a study published in the Journal of the American Medical Association raised some new questions about cancer risks linked with some big diabetes drugs. One month ago, the FDA said it was reviewing data on the two drugs flagged in that study--Merck's ($MRK) Januvia, and Bristol-Myers Squibb ($BMY) and AstraZeneca's ($AZN) Byetta--as well as other drugs, including Novo Nordisk's ($NVO) blockbuster Victoza. Now, as Pharmalot reports, a safety watchdog group has analyzed the FDA's adverse event data, finding more reports of pancreatitis and pancreatic cancer for these drugs compared with older treatments.

The Institute for Safe Medication Practices (ISMP) analysis found that reports of these maladies were about 25 times higher for the GLP-1 class. As individual drugs, Januvia, a DPP-4 inhibitor, along with GLP-1 drugs Byetta and Victoza, were found to have the greatest odds of pancreatitis reports. The odds were lower, but still above those for older treatments, for DPP-4 inhibitors Eli Lilly ($LLY) and Boehringer Ingelheim's Tradjenta/Trajenta; and Bristol-Myers Squibb and AstraZeneca's Onglyza.

Plenty of stuff about results not yet conclusive, but still the most worrying thing is the suggestion that adverse research has been hidden by the big pharma companies.


Apologies if this has been already highlighted elsewhere but I couldn't find it in this forum.

Cheers

LGC

 

[Q007]

I missed this programme, does anyone know if it's available somewhere? YouTube or is there Internet tv version, thanks all, Q


Sent from the Diabetes Forum App

 

[LittleGreyCat]

http://www.channel4.com/programmes/dispatches/4od#3532942

26 days left to view.

Cheers

LGC